Cellek Selim, Rees Rowland W, Kalsi Jas
Wolfson Institute for Biomedical Research, University College London, Gower Street, Cruciform Building, London WC1E 6BT, UK.
Expert Opin Investig Drugs. 2002 Nov;11(11):1563-73. doi: 10.1517/13543784.11.11.1563.
Approximately 50% of men aged over 40 suffer from male erectile dysfunction. Treatment options have widened since the launch of the phosphodiesterase type 5 (PDE5) inhibitor, sildenafil citrate (Viagra trade mark ). However, a certain portion of the patient population, such as diabetics, do not gain significant benefit from PDE5 inhibitors, possibly due to a lack of endogenous nitric oxide. Therefore, new treatment modalities based on the absence of endogenous nitric oxide have been developed. Among them are Rho-kinase inhibitors, soluble guanylate cyclase activators and nitric oxide-releasing PDE5 inhibitors. The available data concerning these compounds will be summarised and their therapeutic potential for male erectile dysfunction will be discussed.
40岁以上的男性中，约50%患有男性勃起功能障碍。自磷酸二酯酶5型（PDE5）抑制剂枸橼酸西地那非（商品名伟哥）上市以来，治疗选择有所增加。然而，一部分患者群体，如糖尿病患者，无法从PDE5抑制剂中获得显著益处，这可能是由于内源性一氧化氮缺乏所致。因此，基于内源性一氧化氮缺乏的新治疗方式已被开发出来。其中包括Rho激酶抑制剂、可溶性鸟苷酸环化酶激活剂和释放一氧化氮的PDE5抑制剂。将总结关于这些化合物的现有数据，并讨论它们对男性勃起功能障碍的治疗潜力。
